Isracann Biosciences Stock Net Income
Isracann Biosciences technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Isracann Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Isracann Biosciences' valuation are provided below:Isracann Biosciences does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Isracann |
Isracann Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Isracann Biosciences' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Isracann Biosciences.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in Isracann Biosciences on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding Isracann Biosciences or generate 0.0% return on investment in Isracann Biosciences over 90 days. Isracann Biosciences is related to or competes with Raphael Pharmaceutical, Avicanna, Voyageur Pharmaceuticals, and Charlottes Web. Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel More
Isracann Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Isracann Biosciences' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Isracann Biosciences upside and downside potential and time the market with a certain degree of confidence.
Isracann Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Isracann Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Isracann Biosciences' standard deviation. In reality, there are many statistical measures that can use Isracann Biosciences historical prices to predict the future Isracann Biosciences' volatility.Isracann Biosciences Backtested Returns
We have found zero technical indicators for Isracann Biosciences, which you can use to evaluate the volatility of the firm. The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Isracann Biosciences are completely uncorrelated.
Auto-correlation | 0.00 |
No correlation between past and present
Isracann Biosciences has no correlation between past and present. Overlapping area represents the amount of predictability between Isracann Biosciences time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Isracann Biosciences price movement. The serial correlation of 0.0 indicates that just 0.0% of current Isracann Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Isracann Biosciences reported net income of (4.69 Million). This is 101.38% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 100.82% higher than that of the company.
Isracann Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Isracann Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Isracann Biosciences could also be used in its relative valuation, which is a method of valuing Isracann Biosciences by comparing valuation metrics of similar companies.Isracann Biosciences is currently under evaluation in net income category among its peers.
Isracann Fundamentals
| Return On Equity | -2.53 | |||
| Return On Asset | -0.35 | |||
| Current Valuation | 2.16 M | |||
| Shares Outstanding | 175.99 M | |||
| Shares Owned By Insiders | 0.50 % | |||
| Price To Book | 9.57 X | |||
| Price To Sales | 8.83 X | |||
| EBITDA | (4.64 M) | |||
| Net Income | (4.69 M) | |||
| Cash And Equivalents | 310.61 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 0.76 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (1.75 M) | |||
| Earnings Per Share | (0.13) X | |||
| Beta | 0.12 | |||
| Market Capitalization | 2.45 M | |||
| Total Asset | 4.09 M | |||
| Z Score | -3.3 | |||
| Net Asset | 4.09 M |
About Isracann Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Isracann Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Isracann Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Isracann Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Isracann Pink Sheet
Isracann Biosciences financial ratios help investors to determine whether Isracann Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Isracann with respect to the benefits of owning Isracann Biosciences security.